Diabetes: Pipeline Understanding Future Trend

Jun 12, 2012
With only Actos® (pioglitazone) slated to lose patent protection in the next several years, increased competition will be important to managing diabetes costs.
Tags
  • Diabetes

Annual U.S. spending on diabetes medicines now exceeds spending on cholesterol drugs, and is forecasted to maintain this top ranking for the foreseeable future.

Based on our analysis, U.S. total drug spending on diabetes is likely to increase 7.1% in 2012, 7.1% in 2013, and 10.2% in 2014.

As reported by the Associated Press, the pipeline for oral diabetes medications is robust. While new medications are often the costliest, a robust pipeline for diabetes is good for payers because additional medicines results in greater competition.

Results from studies of several new diabetes medicines and insulin products, just announced at the American Diabetes Association 72nd Scientific Sessions, give a glimpse at what may be contributing to future diabetes trend.

Researchers presented data on new therapies and experimental delivery systems, including devices that work like an artificial pancreas, monitoring blood sugar and releasing insulin into the patient’s blood when needed.

With 8.3% of the American population, and millions more globally, battling Type-2 diabetes, many more drug manufacturers are focusing their efforts on tackling this condition.

With only one brand-name diabetes medication slated to lose patent protection in the next several years – Actos® (pioglitazone), which is expected to become available as a generic next month – increased competition will be important to managing diabetes costs.

Combining specialized pharmacist consultation, greater generic utilization when appropriate, and novel solutions to improve adherence, Express Scripts is focused on helping diabetes patients manage their condition while lowering their total cost of healthcare.

Author Bio

Lab Staff
comments powered by Disqus